| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $129.5M | — | -7.7% |
| Cost of Revenue | $171.1M | — | +26.3% |
| R&D Expense | $187.7M | — | +20.1% |
| SG&A Expense | $197.6M | — | +26.3% |
| Pre-tax Income | $199.6M | — | +150.1% |
| Income Tax | $32.8M | — | +278.7% |
| Net Income | $166.7M | — | +134.4% |
| EPS (Basic) | $0.13 | — | +116.7% |
| EPS (Diluted) | $0.12 | — | +100.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.40B | -31.0% | +63.1% |
| Total Assets | $53.70B | +6.0% | +42.2% |
| Total Liabilities | $42.89B | +6.8% | +38.0% |
| Stockholders' Equity | $10.81B | +3.1% | +61.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.31B | — | — |
| Investing Cash Flow | -$2.39B | — | -66.2% |
| Financing Cash Flow | $3.11B | — | +118.5% |